An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to evaluate the predictors of response to erythropoietin (hormone secreted by kidney that helps in formation of red blood cells in bone marrow) treatment in participants with cancer (abnormal tissue that grows and spreads in the body until it kills) related anemia (decreased number of red blood cells), receiving chemotherapy (treatment of cancer using drugs).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag Ltd.,Thailand
• Collaborator: Mahidol University
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Participants with non-hematologic malignancy (cancer or other progressively enlarging and spreading tumor, usually fatal if not successfully treated)

• Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment

• Participants receiving chemotherapy

• Participants having indication and planning to receiving erythropoietin (dosage and regimen should comply with Thai FDA approval package insert)

• Participants who have given consent form

Exclusion Criteria:

• Participants with anemia due to other factors (i.e., iron, B12 or folate deficiencies, hemolysis [breakdown in red blood cells], gastrointestinal bleeding, or any active bleeding)

• Participants with previous history of erythropoietin treatment

• Participants who have received blood transfusion within 1 month before starting erythropoietin therapy

• Pregnant or breast-feeding female participants